Florian Marks, Ph.D., is the Deputy Director General of IVI’s Epidemiology, Public Health and Impact (EPIC) unit. This unit encompasses five departments, namely Real-World Evidence, Biostatistics and Data Management, Immunoepidemiology, Antimicrobial Resistance, and Policy and Economic Research. The EPIC unit plays a pivotal role in managing a diverse array of activities including comprehensive epidemiological investigations, undertaking cost-of-illness/cost-effectiveness studies, facilitating training and capacity improvement initiatives, exploring the impact of vaccines on antimicrobial resistance, as well as conducting post-licensure studies to assess vaccine effectiveness and impact.

Additionally, Dr. Marks holds the position of Principal Research Associate at the University of Cambridge in the United Kingdom. He is also an Adjunct Professor at the University of Antananarivo/Madagascar Institute for Vaccine Research, and a Researcher at the Heidelberg Institute for Global Health.

With a distinguished career spanning over 20 years, Dr. Marks has excelled in conducting epidemiological and clinical studies. His vast experience includes the successful execution of large-scale, multi-center research initiatives, notably the Typhoid Fever Surveillance in Africa and the Severe Typhoid in Africa TSAP/SETA programs. These endeavors have yielded valuable data on the incidence and severity of typhoid fever infections in various African countries and helped establish a network of well-operating clinical sites.

Dr. Marks joined IVI in 2006. Prior to his tenure at IVI, he held a researcher position at the Bernhard-Nocht-Institute for Tropical Medicine in Hamburg, Germany. It was during this time that Dr. Marks completed his doctoral degree in malaria epidemiology. While his initial training lies in pharmacy, he has further expanded his academic pursuits, in addition to his doctoral degree, by earning a Master of Public Health from the London School of Hygiene and Tropical Medicine.